• Order within –h –m
  • Free shipping on orders over $250
  • Free Bacteriostatic Water 30ml with $500+ purchase
  • Every batch tested by an independent lab

CJC-1295 no DAC 5mg

$38.00

CAS: 863288-34-0 · MW: 3367.9 Da · Purity: ≥99% by reverse-phase HPLC · Format: 5 mg powder · Identity: ESI-MS confirmed

25 in stock

In Stock

COA verified · View report

Purchase & earn 38 points.
Quantity pricingSave up to 20%
QuantityPrice / vialSavingsAdd
1 vial$38.00–
3 vials$36.10Save 5%
5 vials$34.20Save 10%
10 vials Best value$30.40Save 20%

Purity Guarantee: Every vial is backed by independent third-party domestic lab and Janoshik analytical verification.

  • Third-Party TestedIdentity + purity, every batch. Secondary testing on rotation.
  • Janoshik Analytical3rd party domestic labs verified
  • Same-Day ShippingOrder by 2 PM PST, ships today
  • Ships from California2 Day UPS Air. Free shipping over $250

Research use only. Not for human consumption. Sold to qualified researchers.

Accepted:
  • Visa
  • Mastercard
  • Amex
  • Discover
  • Apple Pay
  • Zelle
  • ACH
  • Bitcoin, 10% off

CJC-1295 without DAC, also called Modified GRF (1-29), is a trimmed and reinforced piece of growth-hormone-releasing hormone. It keeps the active front section of GHRH and adds a few amino-acid swaps that make it sturdier, but it leaves off the “DAC” attachment that turns the longer-acting version into a slow release. Each vial holds 5 mg of freeze-dried powder. Researchers use it to study GHRH-receptor signaling with a shorter, more pulse-like action.

Description

Structure & Identity

This peptide is a 29-amino-acid modified fragment of GHRH, the “1-29” portion that carries the hormone’s activity, with four stabilizing substitutions built in. The “no DAC” label is the important part: DAC (Drug Affinity Complex) is a chemical group that, when present, binds the peptide to blood proteins and stretches its lifetime dramatically. Without it, this version acts more briefly, which is exactly why some research designs prefer it.

Research Background

CJC-1295 research sits at the GHRH receptor and the growth-hormone/IGF-1 axis it activates.

  • GHRH fragment. CJC-1295 (no DAC) is a stabilized 29-residue GHRH fragment; without the DAC group it acts over a shorter window [PMID: 16352683].
  • GH/IGF-1 stimulation. Studies documented prolonged stimulation of GH and IGF-1 secretion [PMID: 16352683].
  • Axis activation. Research tracked activation of the GH/IGF-1 axis and serum readouts [PMID: 19386527].
  • Secretion patterns. Work examined whether GH secretion stays pulsatile under continuous GHRH-analog stimulation [PMID: 17018654].
  • Analytical detection. Detection methods have been developed for CJC-1295 and related peptides [PMID: 30489688].

Note that much of the published CJC-1295 literature involves the longer-acting DAC form; the no-DAC version shares the GHRH-receptor mechanism but with a shorter action. These are research contexts, not approved uses.

Specifications

Attribute Value
Chemical name CJC-1295 no DAC (Modified GRF 1-29)
Also Known As Mod GRF 1-29
Sequence Modified GRF(1-29), 29 residues
CAS number 863288-34-0 
Molecular weight 3367.9 g/mol
Purity ≥99% by reverse-phase HPLC
Length 29 amino acids
Identity Confirmed by ESI mass spectrometry
Physical form Lyophilized powder
Appearance White to off-white solid
Quantity 5 mg per vial
Storage -20°C, protected from light
Solubility Soluble in bacteriostatic or sterile water
Classification Research use only

 

Storage & Handling

Store the sealed vial frozen at -20°C, shielded from light, until needed. Once prepared, keep the solution refrigerated at 2-8°C and use for your research within about two weeks. Warming the vial to room temperature before opening reduces condensation, and avoiding repeated freeze-thaw cycles protects the modified peptide chain.

Storage and Handling Guide

Quality Assurance

CJC-1295 no DAC is produced under research-grade manufacturing controls and verified by an outside lab before it ships. Its purity is measured by reverse-phase HPLC and its identity by mass spectrometry, with testing carried out by independent third-party laboratories, including Janoshik Analytical and domestic US labs. A batch-specific certificate of analysis is provided, so the results can be matched to your exact vial.

Quality & Testing

Frequently Asked Questions

What is CJC-1295 no DAC?

CJC-1295 without DAC, also called Modified GRF (1-29), is a synthetic, stabilized fragment of GHRH studied in growth-hormone-axis research. It is supplied for research use only.

What does “no DAC” mean?

DAC stands for Drug Affinity Complex, a chemical group that binds the peptide to blood proteins and greatly extends how long it lasts. “No DAC” means that group is absent, so this version acts over a shorter window.

How is CJC-1295 different from ipamorelin?

They work through different receptors. CJC-1295 is a GHRH analog acting at the GHRH receptor, while ipamorelin acts at the ghrelin/GHS-R1a receptor. They are studied together because both feed the growth-hormone pathway.

Is CJC-1295 no DAC the same as Modified GRF (1-29)?

Yes, they are two names for the same peptide, a 29-residue GHRH fragment with stabilizing modifications and no DAC group.

Is CJC-1295 FDA approved?

No. CJC-1295 is not an FDA-approved drug or supplement. It is a research-use-only material and is not meant for human or veterinary use.

How should CJC-1295 no DAC be stored?

Keep the powder frozen at -20°C and protected from light. After preparation for research, store at 2-8°C and use within about two weeks.

How is this peptide’s purity verified?

It is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch has a published certificate of analysis.

References

  1. Prolonged stimulation of growth hormone (GH) and IGF-I secretion by CJC-1295. 2006. PMID: 16352683.
  2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. 2009. PMID: 19386527.
  3. Once-daily administration of CJC-1295, a long-acting GHRH analog. 2006. PMID: 16822960.

Additional information

Weight 0.03 kg

Published research

Selected literature

Peer-reviewed studies that describe the research context for this compound. Listed for reference, not as a claim about use.

  • GH/IGF-1 StimulationCJC-1295 and prolonged GH/IGF-I secretion.PubMed 16352683
  • GH-Axis ActivationActivation of the GH/IGF-1 axis by the analog.PubMed 19386527
  • PharmacokineticsOnce-daily GHRH-analog exposure in research.PubMed 16822960
  • Pulsatility ResearchGH secretion under continuous GHRH-analog stimulation.PubMed 17018654
  • Analytical Detection (immuno-PCR)screen for CJC-1295 and related peptides. PubMed 30489688
  • LC-MS/MS ConfirmationConfirming CJC-1295 by LC-MS/MS.PubMed 30938069

Related products